文献速递精神分裂症与精神病性障碍

抗精神病药急性治疗首发精神分裂症:系统综述与网络荟萃分析

Antipsychotic drugs for the acute treatment of patients with a first episode of schizophrenia: a systematic review with pairwise and network meta-analyses.
PubMed 文献 · Lancet Psychiatry · 2017-07-20

该系统综述与配对及网络荟萃分析纳入19项随机对照试验、共2669例首发精神分裂症患者,比较12种抗精神病药急性期疗效与耐受性。结果显示氟哌啶醇可能非最优选择,第二代抗精神病药之间差异不大,证据质量普遍偏低且各药样本量小,治疗选择应主要依据副作用。

要点

  • 氟哌啶醇对首发精神分裂症急性期可能非最优选择。
  • 第二代抗精神病药之间疗效差异不大,选择应主要依据副作用。
  • 证据质量普遍偏低至中等,各药患者数少,解释需谨慎。

核心结论

  • 氟哌啶醇对首发精神分裂症急性期治疗似为次优选择,但第二代抗精神病药之间差异不大。
  • 证据质量普遍偏低且各药患者数少,治疗选择应主要依据副作用。

研究设计与样本

  • 纳入19项随机对照试验,涉及12种抗精神病药、2669例首发精神分裂症急性期治疗患者,其中13项研究报告主要结局数据。

主要发现

  • 奥氮平对阴性症状减少优于氟哌啶醇和利培酮。
  • 多种第二代抗精神病药在全因停药方面优于氟哌啶醇。
  • 奥氮平与至少一次使用抗帕金森病药物相关,喹硫平静坐不能少于氟哌啶醇、阿立哌唑、利培酮和奥氮平,但证据质量极低至低。

关键数值与推荐

  • 主要结局为总体症状变化,次要结局包括阳性与阴性症状变化、分类治疗反应、全因及因无效停药、抗帕金森病药物使用、体重增加、镇静、催乳素释放增加、总体功能和生活质量。
  • 采用随机效应模型计算标准化均数差(SMD)或比值比(OR)及95%CI。

临床怎么用

  • 氟哌啶醇可能不宜作为首发精神分裂症急性期首选。
  • 第二代抗精神病药之间选择应主要依据副作用特征。
  • 因证据质量低且样本量小,临床决策需结合个体情况谨慎解读。

局限性

  • 证据质量普遍偏低至中等。
  • 每种药物的患者数较少。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The first episode of schizophrenia is a pivotal phase of this debilitating illness. Which drug to use remains controversial without a summary of all direct or indirect comparisons of drugs. We did a systematic review with pairwise and network meta-analyses of efficacy and tolerability. METHODS: We searched MEDLINE, Embase, PsycINFO, Cochrane Library, PubMed, Biosis, and ClinicalTrials.gov for randomised controlled trials of antipsychotics for the acute treatment of first-episode schizophrenia, published up to Nov 17, 2016. Our primary outcome was overall change in symptoms. Secondary outcomes were change in positive and negative symptoms, categorical response to treatment, study dropout for any reason and for inefficacy of treatment, use of drugs to treat parkinsonian symptoms, weight gain, sedation, increase in prolactin release, overall functioning, and quality of life. We did the meta-analyses with a random-effects model to calculate standardised mean differences (SMDs) or odds ratios (ORs) with 95% CIs. FINDINGS: We identified 19 relevant randomised controlled trials of 12 antipsychotic drugs that involved 2669 participants. 13 of the studies presented data on the primary outcome. For overall reduction of symptoms, amisulpride (SMD -0·37, 95% CI -0·61 to -0·14), olanzapine (-0·25, -0·39 to -0·12), ziprasidone (-0·25, -0·48 to -0·01), and risperidone (-0·14, -0·27 to -0·01) were significantly more efficacious than haloperidol, but the evidence was very low to moderate quality. Amisulpride was superior for reduction of symptoms to quetiapine (SMD -0·25, 95% CI -0·50 to -0·01). Olanzapine was superior to haloperidol and risperidone for reduction of negative symptoms. Several second-generation antipsychotics were superior to haloperidol in terms of all-cause discontinuation. Olanzapine was associated with at least one use of drugs to treat parkinsonian symptoms and quetiapine with less akathisia than haloperidol, aripiprazole, risperidone, and olanzapine, but, again, evidence was very low to low quality. Molindone was superior to risperidone, haloperidol, and olanzapine in terms of weight gain, and superior to risperidone in terms of increase in prolactin release. INTERPREATION: Haloperidol seems to be a suboptimum treatment option for acute treatment of first-episode schizophrenia, but we found little difference between second-generation antipsychotics. The evidence was generally of low quality and the numbers of patients for each drug were small. Thus, the choice of treatment should be guided primarily by side-effects. FUNDING: German Federal Ministry of Education and Research.

来源:Lancet Psychiatry,查看原文。版权归原作者所有。

引用

  1. Zhu Y, Krause M, Huhn M, et al. Antipsychotic drugs for the acute treatment of patients with a first episode of schizophrenia: a systematic review with pairwise and network meta-analyses. Lancet Psychiatry. 2017. PMID: 28736102. doi:10.1016/S2215-0366(17)30270-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。